Fresenius SE KGaAXSWX:FRE 71 Graham Number is CHF18.12 as of Mar. 2026, which is 100% below its 10-year median of 2.49. GuruFocus rates XSWX:FRE with a GF Score™ of 71/100 and a GF Value™ of CHF33.18 (Fairly Valued). The stock has 5 warning signs investors should review. Among 369 Healthcare Providers & Services companies, Fresenius SE KGaA ranks worse than 59.08% on this metric.
Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.
As of today (2026-06-28), the stock price of Fresenius SE KGaA is CHF36.15. Fresenius SE KGaA's graham number for the quarter that ended in Mar. 2026 was CHF18.12. Therefore, Fresenius SE KGaA's Price to Graham Number ratio for today is 2.00.
The historical rank and industry rank for Fresenius SE KGaA's Graham Number or its related term are showing as below:
XSWX:FRE'
s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.79 Med: 2.49 Max: 3.12
Current: 2.02
During the past 13 years, the highest Price to Graham Number ratio of Fresenius SE KGaA was 3.12. The lowest was 1.79. And the median was 2.49.
XSWX:FRE's Price-to-Graham-Number is ranked worse than 59.08% of 369
companies
in the Healthcare Providers & Services industry
Industry Median: 1.6
vs XSWX:FRE: 2.02
Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.
Fresenius SE KGaA (XSWX:FRE) Graham Number Explanation
Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:
Current price should not be more than 15 times average earnings of the past three years.
Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)
Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.
In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.
Fresenius SE KGaA's Price to Graham number Ratio for today is calculated as
Price to Graham number
=
Share Price (Today)
/
Graham number (Q: Mar. 2026 )
=
36.15
/
18.12
=
2.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Please keep these in mind:
1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.
Fresenius SE KGaA Graham Number Related Terms
Fresenius SE KGaA Graham Number Historical Data
* Premium members only.
The historical data trend for Fresenius SE KGaA's Graham Number can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:FRE vs HCA, THC, DVA: Graham Number Comparison
For the Medical Care Facilities subindustry, Fresenius SE KGaA's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fresenius SE KGaA Price-to-Graham-Number vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Fresenius SE KGaA's Price-to-Graham-Number distribution charts can be found below:
* The bar in red indicates where Fresenius SE KGaA's Price-to-Graham-Number falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fresenius SE KGaA (XSWX:FRE) has a Graham Number of CHF18.12 as of Mar. 2026. The Graham Number values a company based on its per-share earnings and book value. View historical data on Fresenius SE KGaA and its competitors. This is 628% above median its historical median of 2.49. Over the past decade, Fresenius SE KGaA's Graham Number has ranged from 1.79 to 3.12. According to the industry distribution chart, Fresenius SE KGaA ranks #218 out of 369 companies in the Healthcare Providers & Services industry, placing it in the top 59.1%.
Is Fresenius SE KGaA's Graham Number too high?
Fresenius SE KGaA's current Graham Number of CHF18.12 is 628% above median its 10-year median of 2.49. Over the past 10 years, this metric has ranged from a low of 1.79 to a high of 3.12. Based on the distribution chart, Fresenius SE KGaA ranks #218 out of 369 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Fresenius SE KGaA has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fresenius SE KGaA's Graham Number compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Fresenius SE KGaA ranks #218 out of 369 companies for Graham Number. This places Fresenius SE KGaA in the lower half of its industry. The industry median Graham Number is 1.60. Historically, Fresenius SE KGaA's own Graham Number has ranged from 1.79 to 3.12 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Graham Number for a Healthcare Providers & Services company?
The median Graham Number among Healthcare Providers & Services companies is 1.60, based on 369 companies in the industry. Companies in the top quartile (top 25%) have a Graham Number significantly above this median, while those in the bottom quartile fall well below. However, Graham Number should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Graham Number mean?
A high Graham Number can signal that a stock is expensive relative to its fundamentals. The Graham Number values a company based on its per-share earnings and book value. View historical data on Fresenius SE KGaA and its competitors. For the Healthcare Providers & Services industry, the median Graham Number is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fresenius SE KGaA's current Graham Number is CHF18.12, which is 628% above median its own 10-year median of 2.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fresenius SE KGaA stock overvalued right now?
Based on GuruFocus' analysis, Fresenius SE KGaA (XSWX:FRE) is currently considered Fairly Valued. The stock's GF Value™ is CHF33.18, compared to a current price of CHF36.15 — trading 9% above its estimated fair value. The current Graham Number is CHF18.12, which is 628% above median its 10-year median of 2.49. Fresenius SE KGaA's overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Graham Number calculated?
Graham Number is calculated from a company's financial statements. For Fresenius SE KGaA (XSWX:FRE), the current Graham Number is CHF18.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fresenius SE KGaA (XSWX:FRE) Overvalued in 2026?
Based on GuruFocus' analysis, Fresenius SE KGaA stock appears to be overvalued.
The current stock price of CHF36.15 is trading 9% above its estimated GF Value™ of CHF33.18.
GuruFocus considers Fresenius SE KGaA to be Fairly Valued.
Key valuation signals for XSWX:FRE:
Graham Number: CHF18.12 (628% above median its 10-year median of 2.49)
GF Value™: CHF33.18 vs. price of CHF36.15 (9% above fair value)
No single metric tells the full story. See the XSWX:FRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fresenius is a healthcare holding company based in Germany. The company owns a minority stake in dialysis service provider and equipment manufacturer Fresenius Medical Care. The Kabi segment manufactures intravenous drugs, nutrition products, infusion and transfusion therapies, and related pumps. The Helios segment operates private hospitals primarily in Germany and Spain.
71GF Score
Get the complete analysis for XSWX:FRE
Graham Number is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:FRE has been successfully added to your 
